DarioHealth Corp. (DRIO): Price and Financial Metrics


DarioHealth Corp. (DRIO): $14.62

-0.09 (-0.61%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

DRIO POWR Grades


  • DRIO scores best on the Growth dimension, with a Growth rank ahead of 63.58% of US stocks.
  • DRIO's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • DRIO ranks lowest in Quality; there it ranks in the 4th percentile.

DRIO Stock Summary

  • For DRIO, its debt to operating expenses ratio is greater than that reported by just 5.66% of US equities we're observing.
  • With a price/sales ratio of 24.06, DarioHealth Corp has a higher such ratio than 91.4% of stocks in our set.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for DRIO comes in at -40.79% -- higher than that of just 7.08% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to DarioHealth Corp are DCTH, RLAY, NERV, WATT, and PI.
  • DRIO's SEC filings can be seen here. And to visit DarioHealth Corp's official web site, go to mydario.com.

DRIO Valuation Summary

  • DRIO's price/sales ratio is 25.4; this is 605.56% higher than that of the median Healthcare stock.
  • Over the past 100 months, DRIO's price/sales ratio has gone NA NA.
  • DRIO's price/earnings ratio has moved down 1 over the prior 100 months.

Below are key valuation metrics over time for DRIO.

Stock Date P/S P/B P/E EV/EBIT
DRIO 2021-02-22 30.9 6.4 -7.3 -7.7
DRIO 2020-02-03 2.4 4.6 -1.0 -0.8
DRIO 2019-01-09 2.9 2.0 -1.3 -0.6
DRIO 2017-08-18 5.2 4.9 -2.4 -2.0
DRIO 2016-04-25 20.5 -10.7 -2.3 -2.0
DRIO 2014-06-26 NA -17.4 -1.9 -1.4

DRIO Growth Metrics

  • The 2 year net income to common stockholders growth rate now stands at -97.51%.
  • The 5 year net income to common stockholders growth rate now stands at -192.92%.
  • The 5 year price growth rate now stands at -94.44%.
Over the past 34 months, DRIO's revenue has gone up $2,736,000.

The table below shows DRIO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 9.504 -23.723 -37.446
2020-12-31 7.576 -17.736 -33.103
2020-09-30 7.294 -13.828 -30.767
2020-06-30 7.12 -13.418 -26.092
2020-03-31 6.984 -16.283 -26.682
2019-12-31 7.559 -15.725 -20.891

DRIO Price Target

For more insight on analysts targets of DRIO, see our DRIO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $28.41 Average Broker Recommendation 1.5 (Moderate Buy)

DRIO Stock Price Chart Interactive Chart >

Price chart for DRIO

DRIO Price/Volume Stats

Current price $14.62 52-week high $31.85
Prev. close $14.71 52-week low $7.26
Day low $14.45 Volume 137,900
Day high $15.10 Avg. volume 271,128
50-day MA $18.77 Dividend yield N/A
200-day MA $18.10 Market Cap 227.24M

DarioHealth Corp. (DRIO) Company Bio


DarioHealth Corp., a digital health company, develops and commercializes patented and proprietary technologies providing consumers with laboratory-testing capabilities using smart phones and other mobile devices in the United States, Europe, Australia, and Canada. The company's flagship product, Dario, also known as Dario Smart Diabetes Management Solution, is a mobile, real-time, cloud-based, diabetes management solution based on a software application combined with Dario Blood Glucose Monitoring System, a pocket-sized, blood glucose monitoring device. It offers DarioEngage software platform, where the company digitally engages with Dario users and assists them in monitoring their chronic illnesses, as well as provides them with coaching, support, digital communications; and real time alerts, trends, and pattern analysis. DarioHealth Corp. markets its products directly to consumer cash sales, as well as retail pharmacy, hospitals, and distributors; and through online. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was founded in 2011 and is headquartered in Caesarea, Israel.


DRIO Latest News Stream


Event/Time News Detail
Loading, please wait...

DRIO Latest Social Stream


Loading social stream, please wait...

View Full DRIO Social Stream

Latest DRIO News From Around the Web

Below are the latest news stories about DarioHealth Corp that investors may wish to consider to help them evaluate DRIO as an investment opportunity.

DarioHealth partners with Workplace Options and launches behavioral health solutions globally

Marko Geber/DigitalVision via Getty Images DarioHealth (DRIO) launches its digital behavioral health solution that now includes Workplace Options services for its global users. WPO is the largest independent provider of integrated employee wellbeing solutions around the world. "We are thrilled to launch our digital behavioral health platform in partnership with...

Seeking Alpha | July 27, 2021

DarioHealth Launches Behavioral Health Solutions Globally in New Partnership with Workplace Options

DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, today announced the launch of its digital behavioral health solution that now includes Workplace Options (WPO) services for its global users. WPO is the largest independent provider of integrated employee wellbeing solutions around the world.

Yahoo | July 27, 2021

DarioHealth Chosen to Provide Remote Patient Monitoring for Alabama Regional Medical Services

DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today announced it has been selected as a digital health provider by Alabama Regional Medical Services (ARMS), a Federally Qualified Health Center (FQHC) accredited by The Joint Commission and designated as a Primary Care Medical Home serving patients in Jefferson, Shelby, St. Clair, and Blount counties.

Yahoo | July 20, 2021

DRIO: Dario’s Evolving Strategic Vision

By John Vandermosten, CFA NASDAQ:DRIO READ THE FULL DRIO RESEARCH REPORT Revenue Opportunities On July 12, 2021, DarioHealth Corp. (NASDAQ:DRIO) announced the closure of three new employer client contracts derived from wayForward relationship. Average revenue per user for these contracts is expected to be in the low single digit range; however, the agreements were unexpected and provide an

Yahoo | July 16, 2021

DarioHealth Chief Medical Officer Omar Manejwala, M.D., to Present on the Role of Digital Therapeutics in Post-Pandemic Healthcare at DTx Europe

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced Chief Medical Officer Omar Manejwala, M.D. will present "Rebalancing: Digital Therapeutics in a Post-Pandemic Healthcare System" during the virtual conference DTx Europe on July 14th at 5:55 a.m. EST.

Yahoo | July 13, 2021

Read More 'DRIO' Stories Here

DRIO Price Returns

1-mo -31.55%
3-mo -32.56%
6-mo -32.50%
1-year 81.16%
3-year -46.25%
5-year -83.20%
YTD 2.31%
2020 117.84%
2019 -57.95%
2018 -51.25%
2017 -50.77%
2016 -60.75%

Continue Researching DRIO

Want to see what other sources are saying about DarioHealth Corp's financials and stock price? Try the links below:

DarioHealth Corp (DRIO) Stock Price | Nasdaq
DarioHealth Corp (DRIO) Stock Quote, History and News - Yahoo Finance
DarioHealth Corp (DRIO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8757 seconds.